- Home
- CISO vs BOLD Comparison
CISO vs BOLD Comparison
Compare CISO & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CISO
- BOLD
- Stock Information
- Founded
- CISO 2015
- BOLD 2018
- Country
- CISO United States
- BOLD United States
- Employees
- CISO N/A
- BOLD N/A
- Industry
- CISO Computer Software: Prepackaged Software
- BOLD
- Sector
- CISO Technology
- BOLD
- Exchange
- CISO Nasdaq
- BOLD Nasdaq
- Market Cap
- CISO 31.4M
- BOLD 24.4M
- IPO Year
- CISO N/A
- BOLD 2024
- Fundamental
- Price
- CISO $1.13
- BOLD $1.18
- Analyst Decision
- CISO
- BOLD Buy
- Analyst Count
- CISO 0
- BOLD 3
- Target Price
- CISO N/A
- BOLD $4.00
- AVG Volume (30 Days)
- CISO 1.0M
- BOLD 276.3K
- Earning Date
- CISO 08-13-2025
- BOLD 08-11-2025
- Dividend Yield
- CISO N/A
- BOLD N/A
- EPS Growth
- CISO N/A
- BOLD N/A
- EPS
- CISO N/A
- BOLD N/A
- Revenue
- CISO $29,887,603.00
- BOLD N/A
- Revenue This Year
- CISO N/A
- BOLD N/A
- Revenue Next Year
- CISO N/A
- BOLD N/A
- P/E Ratio
- CISO N/A
- BOLD N/A
- Revenue Growth
- CISO N/A
- BOLD N/A
- 52 Week Low
- CISO $0.26
- BOLD $1.00
- 52 Week High
- CISO $3.84
- BOLD $4.72
- Technical
- Relative Strength Index (RSI)
- CISO 51.97
- BOLD N/A
- Support Level
- CISO $0.97
- BOLD N/A
- Resistance Level
- CISO $1.24
- BOLD N/A
- Average True Range (ATR)
- CISO 0.08
- BOLD 0.00
- MACD
- CISO -0.01
- BOLD 0.00
- Stochastic Oscillator
- CISO 63.77
- BOLD 0.00
About CISO CISO Global Inc.
CISO Global Inc provides cybersecurity services. The services are used to protect client's data, financial information, intellectual property, and business reputation. The services include penetration testing, security remediation, compliance auditing, vulnerability assessment, and others. Geographically, the company operates in U.S., Chile and All other countries. The maximum revenue is generated from U.S.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.